Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

PHAC's STBBI guides for healthcare providers and public health professionals outline national recommendations for: the screening and diagnosis of STBBI the treatment of sexually transmitted infections ...

Ten Times to Try Telehealth from Trusted Medical Reference: MerckManuals.com RAHWAY, N.J., September 10, 2024 – Merck Manuals, an authoritative online medical reference, shares advice from experts on ...

Behind positive growth for shares of Merck and Apple, the Dow Jones Industrial Average is up Friday morning. Supported by world-class markets data from Dow Jones and FactSet, and partnering with ...

5, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States ... the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; ...

Distance-learning, online format enables flexible learning at your own pace. The MSc in Palliative Medicine for Health Care Professionals provides high quality distance education for clinicians ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Sanctions for sexual misconduct accounted for one in 10 rulings against health and social care workers in 2023-24, with 249 cases in the past year. But the Professional Standards Authority ...

London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...

According to GlobalData, the recombinant vesicular stomatitis virus – Zaire Ebola virus (rVSV-ZEBOV) vaccine is marketed by Merck under the name Ervebo. It has been available in the US and EU ...

Frespaciguat is under clinical development by Merck and currently in Phase II for Pulmonary Hypertension. According to GlobalData, Phase II drugs for Pulmonary Hypertension have a 59% phase transition ...